The identification of KIT and PDGFRA mutations fundamentally reshaped the biological classification and clinical management of GIST, distinguishing it from other sarcomas and enabling molecularly targeted therapeutic development [11,12,13]. The gene discussed is PDGFRA; the disease is gastrointestinal stromal tumor.